-
AUTHOR INDEX
980
Achkar, Charles C., 451
Adedoyin, Adedayo, 161Adusumalli, Vidyasagar E., 168Agostini,
0., 259
Alary, J., 578Alton, Kevin B., 866Amann, Marianne 1., 788Amin,
Raju D., 139
Anders, M. W., 143, 443, 51 1, 973Anderson, Lucy M., 43
Ardouin, Thierry, 843
Arison, Byron H., 200Arneric, Stephen P., 788
Babu, Satram R., 922Bading J. R., 643Bai, Stephen A., 776Bailey,
G. S., 383, 392
Baillie, Thomas A., 544, 554
Baker, G. B., 756
Balani, Suresh K., 200, 281Baldeck, J.-P., 269
Baradat, M., 578
Barnes, Evelyn R., 14Barnen, Jeffrey L., 947
Batist, Gerald, 165Baudry, Jean Paul, 637Bayne, William F.,
139Bednarski, Patrick J., 419
Bekersky, Ihor, 233
Benet, Leslie Z., 85Bentel, Jacqueline M., 451Benvenuto, J. A.,
428
Bickel, M. H., 26, 31Bickel, Ulrich, 99
Bindra, Dilbir S., 438Birner, Gerbard, 143
Boelsterli, Urs A., 956Bolaji, 0. 0., 756Bonacchi, 0.,
259Bonner, Heather S., 895Boom, Sandra P. A., 148
Boppana, Venkata K., 90
Borchardt, Ronald T., 592
Bories, G., 578Bork, V., 298Boue, Hubert, 544Bourgeois, Blaise,
168
Boyd, Steven A., 880Boylan, John F., 451Bracke, Johan, 129
Branch, Robert A., 161Brennan, James M., 835
Brewer, C. Fred, 412
Brewer, Thomas G., 358
Brouwer, Kim L. R., 120, 224Brown, Darrel Q., 895Brown, Lariy
D., 358
Brown, Ronald P., 858Bruckner, James V., 858Bruelisauer, A.,
194
Burak, Eric S., 43Burcham, D. L., 709Burnette, Thimysta C., 55,
60
Buters, Joroen T. M., 688
Caldwell, John, 616
Carde, Patrice, 843
Carter, John P., 43
Cepa, Steven, 880Cepa, Steven P., 788Chabard, Jean Louis,
637
Chan, Tze-Ming, 866
Chang, Thomas K. H., 673
Charkowski, D. M., 713
Charman, William N., 770
Chauret, N., 969
Chen, Chieh-Fu, 518Chen, Haiyan, 673Chen, 1-wu, 400, 693Chen,
Laishun, 566Chen, Qi, 318Chenery, R. J., 124, 189
Cheng, Haiyung, 139Cheng, Xiaoqin, 206,
820Chesa-Jim#{233}nez,Jesus, 447Chikhale, Prashant J., 592
Chiu, S. H. Lee, 811Chiu, Shuet-Hing Lee, 65 1 , 659Chollet,
Philippe, 637Chou, Cheng-Jen, 518Chow, Hsiao-Hui, 406Christ, David
D., 65Christensen, S. Br#{248}gger,433
Clarke, S. E., 124, 189Clement, Bernd, 486Coddington, Arthur B.,
903
Coffman, B., 713
Colby, Howard D., 903Cole,C.A., 171,304Colletti, Adria E., 183,
625
Collins, Jerry M., 254Colson, K. E., 171Colson, K. L., 304
Combes, R. D., 180
Coppini, G., 259
Couus, R. T., 36, 530, 756Covey, J. M., 428Cravedi, J. P.,
578Crawford, Kim, 849
Crawford, Steven T., 537
Cribb, A. E., 969
Crysler, Carl S., 90
Cui, Donghui, 544Curry, Stephen H., 443Cussac, Catherine,
637
Cyr, Terry, 849
Dalgaard, Lars, 289
Danielson, Terry J., 106Darbyshire, John F., 584Darling, Inger
M., 318Davis, Bernard B., 922
Davis, Charles B., 90Debrauwer, L., 578
Dehal, Shangara S., 937Dekant, Wolfgang, 143, 5 1 1, 667
deLuna, Florencia A., 400
de Miranda, Paulo, 55, 60
Denissen, Jon F., 880
Depuy, Betsy, 139Deschamps de Paillette, Evelyne,
843Devinsky, Orrin, 168
Diamond, Sharon, 65Dich, John, 433Doll, Mark A., 371
Doss, George A., 625, 651
Dow, James, 738
Dreifuss, Fritz E., 168Driver, Craig L, 43
Dulery, Bertrand D., 738
Duncan, C. A., 631Duncan, Carol A., 139
Dunnick, June K., 14Dwyer, Lynn M., 281
East, P., 124, 189Eckhoff, Christian, 154
Egorin, Merrill J., 254Ehlers, Katharine, 928
Eisenhardt, E. U., 26, 31Eisman, Mark S., 443Elmazar, Mohamed M.
A., 928
Erkmen, Kadir, 254Ezan, Eric, 843
Faiman, Morris D., 324
Farmer, Peter B., 616Faught, Edward, 168Faux, S. P.,
180Ferguson, Ronald J., 371Ferrero, James L., 788
Findlay, John W. A., 14Finley, Brent L., 522Finn, R. D.,
643Fischer, V., 269
Fitzgerald, Michael, 788
Fong, Kei-Lai L., 90Forkert, P. Gek, 248French, Jacqueline,
168
Fuentes, A., 428Fujimaki, Masayoshi, 700Fukuyama, Takako,
479
Gal, Joseph, 719
Garbow, J. R., 298Gargas, Michael L., 522Garland, W. A., 211
Garvey, David S., 788George, Malcolm C., 352Gescher, Andreas,
806Gietl Bankmann, Yvonne, 973Gilbert, John D., 139Gillette, James
R., 584
Gimeno, Maria Jos#{233},447Ginos, J., 643
Godeneche, Denise, 637Goldman, Mark E., 200Golsteyn, Lorraine
R., 106Gombar, Charles T., 43Gonzalez, Frank J., 688
Goto, Moritaka, 680
Grabowski, Brian A., 880Granero, Luis, 447Granvil, Camille P.,
165Gray, Kevin, 371Gray, M. R., 36, 530Green, Mitchell D.,
799Gregus, Z., 725
Griffin, G. P., 969Grognet, Jean-Marc, 843
Grubb, M. F., 709Grunnet, Niels, 433
Gudas, Lorraine J., 451Guenthner, Thomas M., 731
Haberer, Lynda J., 113
Haegele, Klaus, D., 738Haegele, Klaus D., 738
Hall, Stephen D., 975Hamilton, Thomas C., 835
Hamman, Mitchell A., 975
Hanano, Manabu, 50
Hanson, Glen, 233
Hara, Ken’ichi, 377, 916Hardwick, James P., 688Hargreaves,
Martin B., 806
Harrell, A. W., 124, 189
Harrington, George W., 43
Harris, T. M., 392
Hasegawa, Takaaki, 8, 561
Hasegawa, Takuro, 377, 916
Hasegawa, Yoshinari, 601
Hashizaki, Maii, 815
Hata, Shunsuke, 377, 916
Hazard, III, E. Starr, 177
Hem, David W., 371Heitz, F., 269Heldrich, Frederick J.,
177Henderson, L., 211
Hendrickx, Jan, 129
Heykants, Joseph, 129Heyn, Heleen, 443, 973Hijioka, Taizo,
680
Hill, Barbara A., 503
Hill, Preston, 880
Hinojosa, Lara M., 503Hirata, Kanako, 889Hirayama, Masashi,
601
Hirobe, Masaaki, 761
Hjortkjaer, Rolf K., 289Hoffman, Jacob M., 200Hollenberg, Paul
F., 343
Hooper, Wayne D., 719Horeck�, J., 338Horton, Tonya L.,
120Hosokawa, Masakiyo, 889
Hosokawa, Shin, 909Huang, S.-M., 709Hultin, Theresa A.,
175Huskey, Su-Er W., 651, 659Hussain, M. Delwar, 36,
530Hutchaleelaha, Athiwat. 406
Iba, Kazuhiko, 294Iga, Tatsuji, 2, 21, 50lnaba, T., 367
-
AUTHOR INDEX 981
Inaba, Tadanobu, 849
Irshaid, Yacoub, 161
Ishii, Yasuyuki, 79
Isnard, Francoise, 843
Ito, Kiyomi, 50
Jackson, Barbara J., 827Jamis-Dow, Carlos A., 254
Janssen, Cor, I 29
Jensen, B. K., 211
Johnson, Marianne K., 880Jones, Barry C., 806Joseph, Gerald L.,
90Juchau, Mont R., 331Jung, Frank, 486Jurima-Romet, Malle, 849
K#{225}llay,Z., 338Kamada, T., 367
Kamin, Marc, 168
Kanekal, Sarathchandra, 74Kang, Young-Sook, 99Karanam, B. V.,
811
Kato, Hideo, 761Kato, Katsuyoshi, 8Kato, Nobuo, 8Kauffman,
Frederick C., 680
Kauffman, Laura R., 200
Kawai, R., 194Kawamori, R., 367
Kawazoe, Sadahiro, 750
Kehrer, James P., 74
Kemeny, N. E., 643Kenmochi, Toshie, 916
Kerns,E.H., 171,304
Kerssebaum, Rainer, 667
Khetarpal, Vinod K., 216
Khokhar, Abdul R., 312
Kido, Yuichiro, 312Kim, Chin, 858Kim, H. J., 725Kirkman, Sandra
K., 175
Kishimoto, M., 367
Kitada, Mitsukazu, 909
Kitareewan, Sutisak, 607
Klaassen, C. D., 725
Klecker, Raymond W., 254
Kolars, Joseph C., 947
Korzekwa, Kenneth R., 688
Koseniauskas, Raymond, 43K#{246}ster,Uta, 667
Kotaki, Hajime, 2, 21Kratochwil, Nicole A., 419
Krejcy, K.. 338
Kretz-Rommel, Anke, 956Krieter, Philip A., 183, 625
Kucharczyk, Norbert, 168
Kuemmerle, Steven C., 343Kumar, Gondi N., 177Kunze, Kent L.,
688, 947Kupfer, David, 937Kurihara, Atsushi, 601
Kuzniecky, Rueben I., 168
Labarre, Pierre, 637
Lacreta, Frank P., 835
Lakshmi, Vijaya M., 922Lam, Gilbert N., 65
Lankford, Susan M., 776
Larson, S. M., 643Lau, Serrine S., 503Lauwers, William, 129
Lavrijsen, Karel, 129
Lee, Charis, 962
Le Jeune, Ludo, 129
Le Kerneau, Joel, 843
Lemaire, M., 194
Lepage, Francis, 544, 554
Levine, Barry S., 498Levine, Walter G., 412
Levy, Ren#{233}H., 544, 554Li, Yan, 566
Lin, Jiunn H., 400, 693
Liu, Lida, 139
Liu, Y., 725
Logsdon, Daniel L., 43Loizou, George D., 511Los, Layne E.,
903
Lotze, Michael, 161
Lown, Kenneth S., 947Luke, 0. M., 304Luo, Gang, 731
Machinist, Joseph M., 788
Macia, Richard A., 90Madan, Ajay, 324Madelmont, Jean Claude,
637Madhu, C., 725Magdalou, Jacques, 659
Magee, Peter N., 43
Mahadevan, S., 269Mammarella, Martha L., 318
Manabe, Tatsuo, 601Mangold, James B., 873
Mangos, Steve, 248
Maniglier-Poulet, Christophe, 206,
820
Mannens, Geert, 129
Mannering, Gilbert J., 663Manning, Randall 0., 858Manzini, S.,
259Marathe, Punit H., 237
Marino, Mark T., 358
Markham, Peter M., 216Maskasame, Chaiyasit, 776Masubuchi,
Yasuhiro, 909
Maurizis, Jean Claude, 637Mayersohn, Michael, 406
Mayol, R. F., 171, 304McCarthy, Dennis J., 443
McLellan, L. I., 392McQuade, R. D., 713
Meuldermans, Willem, 129
Miller, Jr., Wilson H., 451Miller, Randall R., 625, 651Mine,
Takeshi, 294Minery, P., 269
Misslin, P., 194Mizutani, Tamio, 750, 815
Moneti, G., 259
Mong. Seymour, 233Monks, Terrence J., 503Monro, A. M., 341
Moons, Miek M., 148Morris, Marilyn E., 318
Mounetou, Emmanuelle, 637Mukoyama, Hiroko, 79
Nabeshima, Toshitaka, 8, 561
Nadai, Masayuki, 8, 561
Nagata, Kiyoshi, 584Nagata, Osamu, 761Nakagawa, Terumichi,
479
Nakatsuka, Iwao, 294
Namkung, Moses J., 331
Narimatsu, Shizuo, 909
Nau, Heinz, 154, 928
Nelson, Wendel L., 237
Newman, R. A., 428Nicoll-Griffith, D. A., 969
Nielsen, Malene S., 433Nordholm, Lars, 289Norton, Robin L.,
522
Oatis, Jr., John E., 177
O’Brien, Julie A., 200O’Dwyer, Peter J., 835Ohata, Yuka, 479
Ohmori, Shigeru, 909
Ohshima, Natsuo, 21Ohta, Shigeru, 761Ohtani, Michiteru, 2
Ohtawa, Masakatsu, 79
Oide, Hiosumi, 680Oinhart, Igor, 820Okudaira, Noriko, 85
Olah, Timothy V., 139,200
Olsen, Carl E., 433Omata, Yoshiaki, 688O’Neil, James, 65Otto,
Angela M., 419Oturu, Eyitayo M., 799
Ouzzine, Mohamed, 659
Ozols, Robert F., 835
Pan, Y., 298Pardridge, William M., 99
Park, Sang S., 248Parker, Robert J., 254Parli, C. John,
352Paroli, Leonard, 962
Patel, Nita, 143
Patten, Chris J., 566Paustenbach, Dennis J., 522Peggins, James
0., 358Peris, Jos#{233}Esteban, 447Perotti, Beatrice Y. T., 85
Pieraccini, P., 259Piotrovskij, V. K., 338
Piriou, Fran#{231}ois,738Piriou, Fran#{231}ois,738Pitzenberger,
Steven M., 200, 903Pochopin, Nancy L., 770
Pollack,GaryM., 113, 120
Pond, Susan M., 139Pool, William F., 719
Pramanik, Birendra N., 866
Prueksaritanont, Thomayant, 85,
281
PuhI, R. James, 233
Qiao, G. L., 459Quon, C. Y., 709
Raberger, G., 338Rakestraw, Dariel, 65
Ramjit, Harri G., 200,903
Rapp, Maryse, 637Rashed, Mohamed, 544
Redza, Zahrein M., 248
Regnier, B., 289Reuie, Allan E., 975
Rhodes, Gerald R., 90Ridley, W. P., 298Rifkind, Arleen B.,
962Ring, Barbara J., 352Rios,G., 713Rivera, Maria I., 503Riviere,
J. E., 459
Rodrigues, A. David, 788
Rogers, J. Douglas, 139Rooney, Clarence S., 200
Rosenfeld, William, 168
Ross, David, 206, 820
Rotert, Gary A., 788
Rozman, P., 725Rubio, F., 211Rushmore, T. H., 969
Russel, Frans G. M., 148Rustan, Timothy D., 371Ruth, James A.,
206, 820
Sandberg, Jennifer A., 154
Sanders, Ruth A., 537Sarkar, Mohamadi A., 827
Sass, JOm Oliver, 928Satoh, Tetsuo, 889Sawada, Yasufumi, 2, 21,
50
Saxton, P. L., 709
Scatina, JoAnn, 175Schaefer, J., 298
Scher, Howard I., 451Schoen, William R., 651
Schran, Horst F., 873
Schwartz, Michael S., 139Scott, Dennis 0., 438Semple, Hugh A.,
822Shaw, Leslie M., 895Shen, Danny D., 237Shen, Ting-liang, 343
Shoeman, Janice A., 663
Siddik, Zahid H., 312Siest, Gerard, 659
Sigurdson, E. R., 643
Slikker, Jr., William, I 54
Smith, Dennis A., 806Sofia, R. Duane, 168Speerschneider, Petra,
667
Spencer, Anne P., 120
-
982 AUTHOR INDEX
Sperling, Michael, 168
Spielberg, S. P., 969Spooner, Roy W., 106Stein, Herman,
880Stella, Valentino J., 438, 770Stevens, Ruth, 254Stresser, D. M.,
383, 392
Styczynski, P., 713
Su, P., 756Suga, Tetsuya, 889
Sugiyama, Katsumi, 584Sugiyama, Yuichi, 50Sukbuntherng,
Juthamas, 406
Sullivan, James P., 788
Sultatos, Lester 0., 472Surber, Bruce W., 788Suttle, A.
Benjamin, 224
Sutton, Steven C., 438Suzuki, Hiroshi, 50Svensson, Craig K..
572
Szuna, A., 211
Tagaya, Osamu, 561
Tajima, Kazuo, 815
Takahara, Eiji, 761
Takayama, Yu-ichi, 8
Tam, Shui-Pang, 248Tam, Y. K., 36, 530Tang, Cuyue, 544, 554
Taylor, Wesley G., 106Tebbett, Ian R., 498Tedford, C. E.,
713
Tephly, T. R., 713Tephly, Thomas R., 799
Thai,GeraldW., 312
Theoharides, Anthony D., 281
Thomas, Francois, 843
Thornburg, Kelly R., 177
Thummel, Kenneth E., 947Thurman, Ronald G., 680
Tich, Nancy R., 788
Toja, E., 259Tombret, Francis, 544
Torres-Molina, Francisca, 447
Town,C., 211Trager, William F., 975
Triolo, A., 259
Trnovec, 1., 338Tsai, Tung-Hu, 518Tse, Francis L. S.,
873Tulliez, J., 578Tynes, R., 269
Tzimas, Georg, 928
Uchic, John 1., 880
Uchino, Katuyoshi, 2
Urban, Gudrun, 511
Urbanski, James J., 90Urquhart, Michael R., 358
Vage, Chandravathi, 572Vandenbranden, Mark, 975
Vanrollins, M., 713
Varga, Sandor L., 200
Veyre, Annie, 637Vickers, A., 269
Vickers, S., 631Vickers, Stanley, 139
Vincent, S. H., 811Vitarius, James A., 472
Vyas, K. P., 631
Wainer, Irving W., 165
Walle, Thomas, 177Walz, Jr., Frederick G., 607Wang, Eijia,
566
Wang, Li, 8, 561
Wang, Taigi, 165Watkins, ifi, John B., 537
Watkins, Paul B., 947
Waxman, David J., 673Wheeler, S. M., 124, 189Wichmann, Joseph
K., 168
Wienkers, Larry C., 975Williams, D. E., 383, 392
Williams, P. L., 459
Wittfoht, Werner, 928Wittmann, Harald, 667
Wolf, Evelyne, 738Wong, Y. N., 709Woolf, Thomas F., 719
Wrighton, Steven, 975Wrighton, Steven A., 352, 947
Xia, Fangming, 822
Yabuki, Masashi, 294Yamaguchi, Toshiro, 616Yamamoto, Kenji,
815Yamaoka, Kiyoshi, 479Yang, Chung S., 566Yang, Hsueh-Ying L.,
331Yeh, S. D. J., 643Yoshida, Kaoru, 750
Yoshida, Motofumi, 312Yoshida, Toshiaki, 275
Yoshitake, Akira, 294
Yuan, A. S., 631Yuan, Jinhua, 14
Zbaida, Shmuel, 412
Zenser, Terry V., 922
Zhang, Kanyin, 544, 554Thong, Thi, 680Ziemniak, John A., 216
-
983
SUBJECT INDEX
A-74273, in vivo and in vitro morpholine ring metabolism (rats,
dogs,
humans), 880
ABT-41 8, in vitro hepatic metabolism (rats, dogs, cynomolgus
monkeys,
humans), 788
Acetaminophenmetabolism, cytochrome-P450-dependent, effects of
flavonoids, liver
microsomes (rats, humans), 566
sulfation, deficient dietary intake of sulfur (rats), 725
Acetohexamide, carbonyl reductase activity, erythrocytes
(humans), 367Acetone, acute and chronic administration, induction
and regulation of
CYP2E1 in murine liver (mice), 248
2-Acetylaminofluorene, cytochrome-P450-dependent
biotransformation,
cell-free preparations of embryonic tissues (humans), 331
N-Acetylbenzidine, glucuronidation, liver (humans), 922
N-Acetyltransferase alleles, polymorphic, mutant and wild-type,
cloning,
expression, and functional characterization (humans), 371
Acitretin
disposition, oral administration (humans), 211
tissue distribution and elimination, kinetics (rats),
26Acyclovir, prodrugs, valaciclovir
metabolic disposition (rats), 60
metabolic fate and pharmacokinetics (monkeys), 55Adenosine, role
in renal failure induced by bacterial lipopolysaccharide
(rats), 8
Adrenal gland, embryonic tissues, cell-free preparations,
cytochrome-
P450-dependent biotransformation of 2-acetylaminofluorene
(hu-
mans), 331
Aflatoxin B,-DNA adducts, hepatic, reduced levels in vivo,
association with liver
glutathione transferase subunit (Yc2) induction by
indole-3-carbi-
nol (rats), 392metabolism, and cytochromes P450 associated with
bioactivation and
detoxication, indole-3-carbinol and 13-naphthoflavone
induction
(rats), 383
Alendronate, nonlinear kinetics, plasma protein binding and bone
uptake,
400
O6-Alkylguanine-DNA alkyltransferase inhibitor, disposition and
metab-
olism, nude mice bearing human melanoma, 637Allylbenzene,
2,3-epoxide metabolites, detoxication, conjugation with
glutathione, 731
Amidoximes, and N-hydroxylation of pentamidine by liver
cytochrome
P450 2C3 (rabbits), 486
Amifostine, and ethyol, metabolic pathways (BALB/c mouse),
8958-Aminoquinoline, WR24251 1, pharmacokinetics and
kinetic-dynamic
modeling, 358
Amitriptyline, tissue distribution and metabolism, repeated
administration
(rats), 21
Amphetamine, racemic, disposition kinetics of d- and
!-amphetamine,
intravenous administration (rats), 406
Angiotensin-converting enzyme inhibitors, RU44507, active form,
phar-
macokinetics, 601
Angiotensin II receptor antagonists, L-l58,809, disposition
(rats, rhesus
monkeys), 183
Antibiotics, macrolide, in vitro inhibition of terfenadine
metabolism, liver
(humans), 849
Anticonvulsants, remacemide hydrochloride, brain uptake and
biotrans-
formation, 443
Anticyanide drug, candidate, WR24251 I, pharmacokinetics and
kinetic-
dynamic modeling, 358
Antidepressant drugs, nefazodone, characterization of
metabolites, urine
and plasma (humans), 304
Antifungals, azole, in vitro inhibition of terfenadine
metabolism, liver(humans), 849
Antimalarial drug, candidate, WR24251 1, pharmacokinetics and
kinetic-
dynamic modeling, 358
Antiprotozoal drugs, pentamidine, N-hydroxylation, catalyzed by
liver
cytochrome P450 2C3 (rabbits), 486Antiviral agents, deoxyguanine
analogs, as prodrugs, effectiveness and
enzymology, assessment using in vitro systems (rats,
humans),124, 189
‘25I-Ardeparin, distribution and excretion (rats, dogs), 175
Arginine, biological oxidation to /V’3-hydroxyargine, citrullin,
and nitric
oxide, and N-hydroxylation of pentamidine by P450 2C3,
486Avidin, conjugate of, and monoclonal antibody to transferrin
receptor,
biotin bound to, pharmacokinetics and saturable blood-brain
bar-
rier transport, 99
Azo dye substrates, reactivity, determined by electron densities
and redox
potentials, 412
Baculovirus, cDNA-directed expression of human cytochrome P450
3A4,
688
Benzo(a)pyrene, storage and metabolism in liver, role of Kupffer
cells,680
Benzodiazepine, receptor agonist
comparison with GABAA receptor agonist, 50partial (L-663,581),
physiological disposition (laboratory animals), 693
3-[2-(Benzox�ol-2-yl)ethylJ-5-ethyl-6-methylpyridin-2(1H)-one,
see L-
696,229
Bile
disposition of 20(S)-camptothecin, lactone and carboxylate forms
(rats),
438
excretion of taxol, effect of cimetidine, probenecid, and
ketoconazole(rats), 254
flow, influence on ranitidine pharmacokinetics (rats), 224
Biotin, bound to conjugate of avidin and monoclonal antibody to
trans-
femn receptor, pharmacokinetics and saturable blood-brain
barrier
transport, 99
Blood-brain barrier, saturable, transport of biotin bound to
conjugate of
avidin and monoclonal antibody to transferrin receptor, 99
Bone, uptake of alendronate, 400Brain
blood-brain barrier, saturable, transport of biotin bound to
conjugate of
avidin and monoclonal antibody to transfemn receptor, 99
milacemide metabolism, solid-state NMR (rats), 298
muscimol, GABAA receptor occupancy, and glucose metabolic
re-
sponse, linear relationship (mice), 50
remacemide hydrochloride, uptake and transformation, 443
tissue samples, drug concentrations, epileptic patients treated
with fel-
bamate (humans), 168
2-Bromo-(diglutathion-S-yl)hydroquinone, metabolism and
toxicity, in
situ perfused kidney (rats), 503
2-Bromo-3-(diglutathion-S-yl)hydroquinone, metabolism and
toxicity, in
situ perfused kidney (rats), 503
Buprenorphine, enterohepatic circulation, pharmacokinetic
analysis (rats),
2
Butadiene monoxide
solvolysis (letter), 820
solvolytic formation of l,2-dichloro-3,4-epoxybutane,
physiological
conditions, 206
L-Buthionine SR-sulfoximine, stereoselective pharmacokinetics,
patients
with cancer, 835
6-tert-Butyl-2,3-epoxy-l,4-benzoquinone, carbonyl reduction by
liver ml-
crosomes and cytosol (rats), 815
3-tert-Butyl-4-hydroxyanisole, metabolite, carbonyl reduction by
liver
microsomes and cytosol (rats), 815
-
984 SUBJECT INDEX
probes, theophylline N-demethylations, 827
20(S)-Camptothecin, lactone and carboxylate forms, urinary and
biliary
disposition (rats), 438
Carbonic anhydrase inhibitors, see Dorzolamide
Carbonyl
reductase activity, acetohexamide, erythrocytes (humans),
367
reduction, 6-tert-butyl-2,3-epoxy-l,4-benzoquinone, by liver
micro-
somes and cytosol (rats), 815
Carboxylesterases, hepatic microsomal, induction caused by
dietary cx-posure to di(2-ethylhexyl)phthalate, species
differences, 889
R( + )- and S( - )-Carvedilol, oxidation by liver microsomes,
evidence forstereoselective oxidation and characterization of
cytochrome P450
isozymes (rats), 700
CCNU, see l-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea
cDNA, -directed expression of human cytochrome P450 3A4,
usingbaculovirus, 688
Cefadroxil, renal excretion mechanisms, studies, 447
Chloramphenicol, evidence for new metabolic pathways (ducks),
578
l-(2-Chloroethyl)-3-cyclohexyl-l-nitrosourea, suppression of
cytochrome
P450 2Cl 1 messenger RNA levels, modulation of liver
microso-
mal cyclophosphamide and ifosphamide activation (rats),
673p-Chloronitrobenzene, pharmacokinetic study (rats), 275
m-Chlorophenylpiperazine, major urinary metabolite, isolation
and iden-
tification(rats),171
Cholinergic channel activators, ABT-41 8, in vitro hepatic
metabolism(rats, dogs, cynomolgus monkeys, humans), 788
Chromium, urinary excretion following ingestion of chromium
picolinate
(humans), 522Cimetidine
effect on taxol metabolism (rats), 254interaction with oxidized
and prereduced microsomal cytochrome P450,
180
renal tubular transport, isolated perfused kidney (rat),
148Cisplatin, analog bearing a 1,2-diphenylethylenediamine ligand,
revers-
ible and irreversible interactions with plasma and plasma
proteinsin vitro, 419
Citrulline, biological oxidation of arginine, 486
Cocaine, pharmacokinetics, ethanol pretreatment (rats), 498
Codeine, toxicokinetics, two-year dosed feed study (rats),
14Cyclophosphamide
activation, liver microsomes, modulation by
l-(2-chloroethyl)-3-cyclo-
hexyl-l-nitrosourea (rats), 673
metabolism by lipoxygenases, 74Cyclosporine derivative, SDZ 1MM
125, absorption and disposition, sin-
gle and repeated administration (rats), 194Cyclosporin G,
pharmacokinetics and metabolism (humans), 873
Cytochrome P450associated with bioactivation and detoxification
of a.flatoxin B , , influ-
ence of indole-3-carbinol and �-naphthoflavone (rats),
383-dependent acetaminophen metabolism, effects of flavonoids,
liver mi-
crosomes (rats, humans), 566-dependent biotransformation,
2-acetylaminofluorene, cell-free prepa-
rations of embryonic tissues (humans), 331
genetic and developmental diversity, warfarin and progesterone
metab-olism, hepatic microsomes, inbred strains (rats), 607
isozymes, involvement in FK 506 metabolism, liver microsomes
(hu-mans), 811
isozymes, involvement in oxidation of R( m+)- and S(
)-carvedilol,liver microsomes (rats), 700
isozymes, involvement in propranolol metabolism, liver
microsomes,role of CYP2D6 and CYP1A2 (humans), 909
microsomal, oxidized and prereduced, interaction of cimetidine
with,180
Cytochrome P450 1A1
2,3,7,8-tetrachlorodibenzo-p-dioxin-induced, hepatocytes as
major lo-
cus, embryo liver (chicks), 962
Cytochrome P450 1A2
probes, theophylline N-demethylations, 827
role as N-desisopropylase, propranolol metabolism, liver
microsomes(humans), 909
2,3,7,8-tetrachlorodibenzo-p-dioxin-induced, hepatocytes as
major lo-
cus, embryo liver (chicks), 962
Cytochrome P450 2Binduction following dietary administration of
linopirdine (mice), 65
involvement in methoxychlor metabolism (rats, humans),
937Cytochrome P450 2B1, purified liver, inactivation by
N-methylcarbazole
(rats), 343
Cytochrome P450 284, purified liver, inactivation by
N-methylcarbazole(rabbits), 343
Cytochrome P450 2C3, liver, N-hydroxylation of pentamidine
(rabbits),
486Cytochrome P450 2C6, mediation of biotransformation of
dapsone and
monoacetyldapsone to hydroxylamine metabolites, liver micro-
somes (rats), 572Cytochrome P450 2C9, relationship between
levels and prototypic cats-
lytic activities, liver microsomes (humans), 975
Cytochrome P450 2Cl 1
mediation of biotransformation of dapsone and monoacetyldapsone
tohydroxylamine metabolites, liver microsomes (rats), 572
messenger RNA levels, suppression by
l-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, 673
oxidation of R(+)- and S(-)-carvedilol, liver microsomes (rats),
700purified, formation of l6a-hydroxyandrostenedione from
testosterone
(rats), 584
Cytochrome P450 2Dl, oxidation of R(+)- and S(-)-carvedilol,
livermicrosomes (rats), 700
Cytochrome P450 2D6involvement in metabolism of
5-hydroxytryptamine antagonists, 269
microsomal preparation, metabolism of methoxyphenamine in
vitro,
756role as nng-hydroxylase, propranolol metabolism, liver
microsomes
(humans), 909
Cytochrome P450 2Elinduction and regulation in murine liver,
acute and chronic acetone
administration (mice), 248
metabolism of 1,1,2,3,3,3-hexafluoropropyl methyl ether, 667
Cytochrome P450 3A
induction following dietary administration of linopirdine
(mice), 65murine, induction by usnic and vulpinic acids, 663role in
in vitro metabolism of zatosetron, 352
Cytochrome P450 3Al, mediation of biotransformation of dapsone
andmonoacetyldapsone to hydroxylamine metabolites, liver
micro-somes (rats), 572
Cytochrome P450 3A4cDNA-directed expression using baculovirus
(humans), 688expression in small bowel, interpatient heterogeneity,
lack of prediction
by erythromycin breath test, 947involvement in FK 506
metabolism, liver microsomes (humans), 811
Cytochrome P450 3A5, expression in small bowel, interpatient
heteroge-neity, lack of prediction by erythromycin breath test,
947
Cytosol, liver, carbonyl reduction of
6-tert-butyl-2,3-epoxy-l,4-benzoqui-
none (rats), 815
Dapsone
amino acid prodrugs, pharmacokinetics, 770
biotransformation to hydroxylamine metabolites, mediation by
cyto-
chrome P450 2C6/2Cll and 3A1, liver microsomes (rats), 572
N-hydroxylation, monoacetyldapsone inhibition, liver microsomes
(hu-mans, rats), 161
-
SUBJECT INDEX 985
Ethanol
pharmacokinetics, 770
DEET, dermal absorption, pharmacokinetic assessment (cattle),
106N-Deethylated dorzolamide, in vitro binding to erythrocytes
(humans),
377
Deoxyguanine analogs, as prodrugs of antiviral agents,
effectiveness and
enzymology, assessment using in vitro systems (rats,
humans),124, 189
Dichloroacetylene, glutathione and cysteine S-conjugates,
glutathione-
dependent biosynthesis and bloactivation, tissues and
subcellular
fractions (rats), 143
I ,2-Dichloro-3,4-epoxybutane, solvolytic formation from
butadiene mon-
oxide, physiological conditions, 206
2,2-Dichloro- I , I , 1-trifluoroethane (HCFC- I 23), gas-uptake
pharmacoki-netics, 5 1 1
S-(l,2-Dichlorovinyl)glutathione, glutathione-dependent
biosynthesis and
bioactivation, tissues and subcellular fractions (rats), 143
s- I ,2-Dichlorovinyl-L-cysteine, glutathione-dependent
biosynthesis andbioactivation, tissues and subcellular fractions
(rats), 143
Diclofenac
covalent adduct formation to hepatic microsomal proteins,
mechanism
(rats), 956
enterohepatic circulation, disposition kinetics, new analysis
method
(rats), 479
Diethyldithiocarbamate methyl ester, NADPH-dependent,
regioselective
S-oxidation, liver microsomes (rats),
324N,N-Diethyl-m-toluamide, see DEET
l,3-Di(4-imidazolino-2-methoxyphenoxy)propanelactate,
pharmacoki-
netics (dogs), 233
Diltiazem
effects on disposition and metabolism of enantiomers of
propranolol,
multiple oral dosing (dog), 776
kinetic interactions with lidocaine, diphenhydramine, and
verapamil,
isolated perfused liver (rats), 530time-dependent kinetics,
mechanisms, isolated perfused liver (rats), 36
Diphenhydramine, kinetic interaction with diltiazem, isolated
perfused
liver (rats), 530
Di(2-ethylhexyl)phthalate, dietary exposure, induction of
hepatic micro-somal carboxylesterases, species differences, 889
DMP 323, pharmacokinetics (rats, dogs), 709DNA adducts,
aflatoxin-, hepatic, reduced levels in vivo, association with
liver glutathione transferase subunit (Yc2) induction by
indole-3-
carbinol (rats), 3921,2-Diphenylethylenediamine ligand,
cisplatin analog bearing, reversible
and irreversible interactions with plasma and plasma proteins
invitro, 419
Dolastatin 10, preclinical pharmacology, 428Dopamine D-l
receptor antagonists
SCH 23390, glucuronidation by liver microsomes (humans), 713SCH
39166, glucuronidation by liver microsomes (humans), 713
Dorzolamide
and metabolite, N-deethylated dorzolamide, in vitro binding to
eryth-rocytes (humans), 377
in vitro metabolism, liver microsomes (rats), 916
Enprofylline, pharmacokinetics and protein binding, alterations,
hyperbi-lirubinemia, rats, 561
Erythrocytes
binding of dorzolamide and N-deethylated dorzolamide, in vitro
(hu-mans), 377
carbonyl reductase activity for acetohexamide (humans), 367
Eryth.romycin breath test, lack of prediction of interpatient
heterogeneity,
expression of CYP3A4 and CYP3A5 in small bowel, 947
Estragole, 2,3-epoxide metabolites, detoxication, conjugation
with gluts-
thione, 731
cotreatment, suppression of in vivo clearance of
N-nitrosodimethyl-amine (mice), 43
pretreatment, cocaine pharmacokinetics (rats), 498
Ethyol, and amifostine, metabolic pathways (BALB/c mouse),
895Etretinate, tissue distribution and elimination, kinetics
(rats), 31
Exercise, chronic voluntary, effect on hepatobiliary clearance
of chemi-
cals (rats), 537
Famotidine, renal excretion, renal failure induced by bacterial
lipopoly-
saccharide (rats), 8
Felbamate, drug concentrations, brain tissue samples, epileptic
patients(humans), 168
Fibrinogen receptor antagonists, MK-852, disposition (rats,
dogs), 631Finasteride, biotransformation, in vitro, hepatic
microsomes, isolation and
FK 506characterization of metabolites (rats), 79
metabolism, liver microsomes, involvement of cytochrome
P450isozymes, investigation (humans), 8 1 1
metabolism, male and female liver microsomes (rats), 85
Flavonoids, effects on cytochrome-P450-dependent acetaminophen
me-
tabolism, liver microsomes (rats, humans), 566
5-[’8F]Fluoro-2-deoxyuridine, hepatic arterially injected,
transport limits
cellular entry, intrahepatic tumors (humans), 643
Glucagon, effects on propranolol disposition, single-pass
isolated, per-fused liver (rats), 822
Glucose, metabolic response, and GABAA receptor occupancy of
musci-mol, linear relationship, conscious brain (mice), 50
Glucuronic acid, moiety, retention in diclofenac-protein
adducts, hepaticmicrosomes (rats), 956
N-Glucuronidation reactions, methylbiphenyl tetrazole,
methylbiphenyl
triazole, and methylbiphenyl imidazoleregioselectivity of
N-glucuronidation, recombinant UDP-glucuronosyl-
transferases stably expressed in V79 cells (humans, rats),
659relative N-glucuronidation reactivity, hepatic microsomes (rats,
mon-
keys, humans), 651
Glutamate antagonist, neuroprotective, see NBQX
Glutathione
conjugation with, detoxication of 2,3-epoxide metabolites of
allylben-zene and estragole, 731
-dependent biosynthesis and bioactivation, glutathione and
cysteine
S-conjugates of dichloroacetylene, tissues and subcellular
fractions
(rats), 143
intraperitoneal administration with tetraplatin,
pharmacokinetics (mice),
312
S-transferases, cytosolic, increased cosedimentation with
microsomal
fractions prepared from frozen liver (rats), 964
transferase subunit (Yc2), liver, induction by indole-3-carbinol
(rats),
392
Growth hormone-releasing peptide (SK&F 1 10679),
disposition, intrave-nous or subcutaneous administration (rats,
dogs), 90
Heart, embryonic tissues, cell-free preparations,
cytochrome-P450-depen-
dent biotransformation of 2-acetylaminofluorene (humans),
331Hematopoiesis, negative regulators, seraspenide,
pharmacokinetics, 843
Heparin, ‘25I-ardeparin, distribution and excretion (rats,
dogs), 175Hepatocytes
locus of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced
CYPI-relatedP450s, TCDDAA and TCDDAHH, embryo liver (chicks),
962
thapsigargin metabolism (rats), 433
1,1,2,3,3,3-Hexafluoropropyl methyl ether, metabolism, role of
cyto-chrome P450 2E1 , 667
Human immunodeficiency virus- 1protease inhibitors, DMP 323,
pharmacokinetics (rats, dogs), 709
-
986 SUBJECT INDEX
reverse transcriptase inhibitors, i-696,229, metabolism (rats,
humans),
200, 281
16a-Hydroxyandrostenedione, formation from testosterone,
purified P450
2Cl 1 (rats), 584N#{176}-Hydroxyarginine, biological oxidation
of arginine, 486
Hydroxylamine metabolites, biotransformation of dapsone and
mono-
acetyldapsone, mediation by cytochrome P450 2C6/2C1 1 and
3A1,
liver microsomes (rats), 572
6a-Hydroxytaxol, isolation and identification, liver microsomes
(hu-
mans), 177
3-Hydroxy-thiomethyl metabolites, production, hepatic metabolism
of
spironolactone, 9035-Hydroxytryptamine antagonists
ondansetron, metabolism, CYP2D6 involvement, 269tropisetron,
metabolism, CYP2D6 involvement, 269
Hyperbilirubinemia, enprofylline, alterations in
pharmacokinetics andprotein binding, rats, 561
Hypoglycemic agents, pioglitazone, disposition and metabolism
(rats),
625
Ifosfamide
activation, liver microsomes, modulation by
l-(2-chloroethyl)-3-cyclo-
hexyl-l-nitrosourea (rats), 673
enantiomers, enantioselective N-dechloroethylation, influence of
phe-
nobarbital induction (rats), 165
Immunosuppressants
FK 506, metabolism, liver microsomes, involvement of
cytochromeP450 isozymes, investigation (humans), 81 1
FK 506, metabolism, male and female liver microsomes (rats),
85Indole-3-carbinol
induction of aflatoxin B, metabolism and cytochromes P450
associatedwith aflatoxin B, bioactivation and detoxification
(rats), 383
induction of liver glutathione transferase subunit with high
activity
toward aflatoxin B, exo-epoxide (rats), 392Insulin, effects on
propranolol disposition, single-pass isolated, perfused
liver (rats), 822
Intestine, site-dependent hydrolysis, vaiproate and morphine
glucuronide
(rats), 120
Isbufylline, metabolism (humans), 259
Ketoconazole, effect on taxol metabolism (rats), 254
Kidney
cefadroxil, excretion mechanisms, 447
cimetidine, renal tubular transport (rats), 148
embryonic tissues, cell-free preparations,
cytochrome-P450-dependent
biotransformation of 2-acetylaminofluorene (humans), 331
failure, bacterial lipopolysaccharide-induced, renal excretion
of famo-tidine and role of adenosine (rats), 8
inorganic sulfate, transport, inhibition by salicylate, membrane
vesicle
preparations (rats), 318metabolism and toxicity of
2-bromo-(diglutathion-S-yl)hydroquinone
and 2-bromo-3-(diglutathion-S-yl)hydroquinone (rats), 503
Kupffer cells, role in storage and metabolism of benzo(a)pyrene,
liver,680
L-l58,809, disposition (rats, rhesus monkeys), 183
L-663,58l, physiological disposition (laboratory animals),
693
L-696,229, metabolism (rats, humans), 200, 281
(R),(R)-Labetalol, urinary metabolites, 866
Lichen constituents, usnic and vulpinic acids, induction of
murine cyto-chrome P450 3A, 663
Lidocaine, kinetic interaction with diltiazem, isolated perfused
liver (rats),
530
Linopirdine, dietary administration, induction of cytochromes
P450 2B
and 3A (mice), 65
Lipopolysaccharide-induced renal failure, excretion of
famotidine androle of adenosine (rats), 8
Lipoxygenases, metabolism of cyclophosphamide, 74
LiverN-acetylbenzidine, glucuromdation (humans),
922benzo(a)pyrene, storage and metabolism, role of Kupifer cells,
680cytochrome P450 2C3, N-hydroxylation of pentamidine (rabbits),
486diltiazem, time-dependent kinetics, mechanisms (rats), 36
embryo, tetrachlorodibenzo-p-dioxin-induced CYP1-related P450s,
TC-DDAA, and TCDDAHH, hepatocytes as major locus (chicks), 962
embryonic tissues, cell-free preparations,
cytochrome-P450-dependent
biotransformation of 2-acetylaminofluorene (humans), 331
enterohepatic circulation
buprenorphine, pharmacokinetic analysis (rats), 2diclofenac,
disposition kinetics, new analysis method (rats),
479norbuprenorphine, pharmacokinetic analysis (rats), 2
recirculation, pharmacokinetics of ranitidine (rats),
224enterohepatic cycling, N#{176}-nitro-L-arginine (rats),
338hepatobiliary clearance, endogenous and exogenous chemicals,
effect of
chronic voluntary exercise (rats), 537
induction and regulation of CYP2E1, acute and chronic acetone
admin-istration (mice), 248
intrahepatic tumors, hepatic arterially injected
5-[’8F]fluoro-2-deoxy-
uridine, transport limits cellular entry (humans), 643
kinetic interactions of lidocaine, diphenhydramine, and
verapamil with
diltiazem (rats), 530
metabolism of ABT-418, in vitro (rats, dogs, cynomolgus
monkeys,humans), 288
metabolism of L-696,229 (rats, humans), 200, 281
metabolism of spironolactone, production of 3-hydroxy-thiomethyl
me-
tabolites, 903
milacemide metabolism, solid-state NMR (rats), 298
propranolol disposition, presence and absence of insulin and
glucagon(rats), 822
purified cytochmme P450, inactivation by N-methylcarbazole
(rats,rabbits), 343
UDP-glucuronosyltransferase, stable expression, with activity
toward
steroid and xenobiotic substrates (humans), 799
Liver microsomes
azoreductase activity, 412
carbonyl reduction of 6-tert-butyl-2,3-epoxy-l,4-benzoquinone
(rats),815
carboxylesterases, induction, caused by dietary exposure to
di(2-ethyl-
hexyl)phthalate, species differences, 889R(+)- and S(-
)-carvedilol oxidation, evidence for stereoselective oxi-
dation and characterization of cytochrome P450 isozymes
(rats),
700
cyclophosphamide and ifosphamide activation, modulation by
1-(2-
chloroethyl)-3-cyclohexyl-l-nitrosourea (rats), 673
cytochrome P450-dependent acetaminophen metabolism, effects of
fla-
vonoids (rats, humans), 566levels and prototypic catalytic
activities, relationship (humans), 975dapsone and
monoacetyldapsone, biotransformation to hydroxylamine
metabolites, mediation by cytochrome P450 2C6/2C1 I and 3A1
(rats), 572dapsone N-hydroxylation, monoacetyldapsone inhibition
(humans,
rats), 161diethyldithiocarbamate methyl ester, regioselective
S-oxidation (rats),
324
dopamine D-l receptor antagonists, glucuronidation (humans),
713dorzolamide, in vitro metabolism (rats), 916finasteride
biotransformation, isolation and characterization of metab-
olites (rats), 79
FK 506 metabolism (rats), 85
-
SUBJECT INDEX 987
FK 506 metabolism, involvement of cytochrome P450 isozymes,
in-vestigation (humans), 811
N-glucuronidation reactivity, relative, methylbiphenyl
tetrazole, meth-
ylbiphenyl triazole, and methylbiphenyl imidazole (rats,
monkeys,humans), 651
N-hydroxylation of pentamidine (humans), 4866a-hydroxytaxol,
isolation and identification (humans), 177
p-nitrophenol hydroxylase, inhibition by small aromatic and
heterocy-
clic molecules (rats), 806
proteins, covalent adduct formation of diclofenac, mechanism
(rats),
956pseudoracemic propranolol, metabolic kinetics (humans),
237
warfarin and progesterone metabolism, inbred strains (rats),
607Lomustine, see l-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea
Lung, embryonic tissues, cell-free preparations,
cytochrome-P450-depen-
dent biotransformation of 2-acetylaminofluorene (humans),
331
Magnolol, disposition, intravenous bolus and infusion (rabbits),
518
[3H1-I-Menthol, metabolic fate (rats), 616Methoxychlor,
metabolism by hepatic P450 monooxygenases, dual path-
ways involving novel ortho ring-hydroxylation by CYP2B
(rats,
humans), 937
Methoxyphenamine, metabolism in vitro by CYP2D6 microsomal
prepa-ration, 756
Methylbiphenyl imidazoleN-glucuronidation reactivity, hepatic
microsomes (rats, monkeys, hu-
mans), 651regioselectivity of N-glucuronidation, recombinant
UDP-glucuronosyl-
transferases stably expressed in V79 cells (humans, rats),
659Methylbiphenyl tetrazole
N-glucuronidation reactivity, hepatic microsomes (rats, monkeys,
hu-
mans), 651regioselectivity of N-glucuronidation, recombinant
UDP-glucuronosyl-
transferases stably expressed in V79 cells (humans, rats),
659Methylbiphenyl triazole
N-glucuronidation reactivity, hepatic microsomes (rats, monkeys,
hu-
mans), 651regioselectivity of N-glucuronidation, recombinant
UDP-glucuronosyl-
transferases stably expressed in V79 cells (humans, rats),
659N-Methylcarbazole, inactivation of cytochrome P450 (rats,
rabbits), 343
L-a-Methyldopa, metabolism, in vivo, comparison with metabolism
in
cultured intestinal epithelial cell monolayers (humans), 592
4-[4-(4-Methylphenyl)-phenylmethoxy-1 -piperidinyljbutyric acid,
dispo-sition, inter-individual differences, possible involvement of
genetic
polymorphism (rats), 761
Milacemide, metabolism in liver and brain slices, solid-state
NMR (rats),
298MK-852, disposition (rats, dogs), 631
Mofegiline, novel carbamate metabolites (dogs, humans), 738
Monoacetyldapsone, biotransformation to hydroxylamine
metabolites,mediation by cytochrome P450 2C6/2Cl I and 3A1, liver
micro-somes (rats), 572
Monoamine oxidase B, inhibitors, Mofegiline, novel carbamate
metabo-
lites (dogs, humans), 738
Morphine glucuronide, site-dependent intestinal hydrolysis
(rats), 120
Muscimol, GABAA receptor occupancy, and glucose metabolic
response,
linear relationship, conscious brain (mice), 50
NAc-SDKP, see SeraspenideNADPH-dependent, regiosclective
S-oxidation, diethyldithiocarbamate
methyl ester, liver microsomes (rats), 324�-Naphthoflavone,
induction of aflatoxin , metabolism and cytochromes
P450 associated with aflatoxin B , bioactivation and
detoxification(rats), 383
NBQX (6-nitro-7-sulfamoyl-benzo(f)-quinoxaline-2,3-dione),
pharmaco-kinetics (mice, rats, dogs), 289
Nefazodone, characterization of metabolites, urine and plasma
(humans),304
Nithc oxide, biological oxidation of arginine, 486
N#{176}-Nitro-L-arginine, enterohepatic cycling (rats),
338N-Nitrosodimethylamine, in vivo clearance, suppression by
cotreatment
with ethanol (mice), 43
p-Nitrophenol hydroxylase, in liver microsomes, inhibition by
small aro-
matic and heterocyclic molecules (rats), 806Norbuprenorphine,
enterohepatic circulation, pharmacokinetic analysis
(rats), 2
NSC 376128, see Dolastatin 10Nuclear magnetic resonance,
solid-state, milacemide metabolism, liver
and brain slices (rats), 298
Ondansetron, metabolism, CYP2D6 involvement,
269Organophosphates
paraoxon, detoxification by serum A-esterase, kinetic mechanism
(hu-mans), 472
parathion, percutaneous absorption, biotransformation and
systemicabsorption, in vivo (swine), 459
Paraoxon, detoxification by serum A-esterase, kinetic mechanism
(hu-
mans), 472Parathion, percutaneous absorption, biotransformation
and systemic ab-
sorption, in vivo (swine), 459
Pentamidine, N-hydroxylation, catalyzed by liver cytochrome P450
2C3(rabbits), 486
Peroxisome proliferators, di(2-ethylhexyl)phthalate, dietary
exposure, in-duction of hepatic microsomal carboxylesterases,
species differ-
ences, 889
Phenobarbital, induction, influence on enantioselective
N-dechloroethyla-
tion of ifosfamide enantiomers (rats), 165
3-Phosphoadenosine 5-phosphosulfate, homeostasis,
acetaminophen-
induced alterations, deficient dietary intake of sulfur (rats),
725
Pioglitazone, disposition and metabolism (rats), 625Plasma
all-trans- and 9-cis-retinoic acid, oral administration,
differences in
pharmacokinetic properties (mice), 451
and plasma proteins, in vitro, reversible and irreversible
interactions of
a cisplatin analog with, 419
metabolites of isbufylline, isolation, identification, and
synthesis (hu-
mans), 259
metabolites of nefazodone, characterization (humans), 304
metabolites of 9-cis-retinoic acid, 928
protein binding, alendronate, 400
Primaquine, analog WR24251 I, pharmacokinetics and
kinetic-dynamic
modeling, 358
Probenecid
effect on total metabolism (rats), 254interactions with NBQX
(mice, rats, dogs), 289
Proestrogenic pesticides, methoxychlor, metabolism by hepatic
P450 mo-nooxygenases, dual pathways involving novel ortho
ring-hydroxy-
lation by CYP2B (rats, humans), 937
Progesterone, metabolism by hepatic microsomes, inbred strains
(rats),
607
Propranolol
disposition, single-pass isolated, perfused liver, presence and
absence of
insulin and glucagon (rats), 822
enantiomers, disposition and metabolism, effects of diltiazem,
multiple
oral dosing (dog), 776metabolism, involvement of cytochrome P450
isozymes, liver micro-
somes, role of CYP2D6 and CYPIA2 (humans), 909
-
988 SUBJECT INDEX
pseudoracemic, metabolic kinetics, liver microsomes (humans),
237
Pseudoracemic propranolol, metabolic kinetics, human liver
microsomes,237
Quinidine inhibition, pseudoracemic propranolol, metabolic
kinetics, liver
microsomes (humans), 237
Ranitidine, pharmacokinetics, influence of bile flow (rats),
224
Remacemide-glycine hydrolase, tissue distribution and
stereoselectivity,
973
Remacemide hydrochloride, brain uptake and biotransformation,
443
Renin inhibitors, orally active, A-74273, in vivo and in vitro
morpholine
ring metabolism (rats, dogs, humans), 880Retinoic acid
aIl-trans- and 9-cis-, oral administration, differences in
pharmacokineticproperties, plasma (mice), 451
pharmacokinetics, intravenous administration (monkeys), 154
all-trans-4-oxo, pharmacokinetics, intravenous administration
(mon-
keys), 154
9-cis- and all-trans-, oral administration, differences in
pharmacokineticproperties, plasma (mice), 451
limited placental transfer to embryos (mice, rats), 928major
plasma metabolites, 9,l3-dicis-retinoic acid, 9289,l3-dicis-
identification as major plasma metabolite of 9-cis-retinoic
acid, 928
limited placental transfer to embryos (mice, rats), 928I 3-cis-,
pharmacokinetics, intravenous administration (monkeys), 154
13-cis-4-oxo, pharmacokinetics, intravenous administration
(monkeys),
154Retinoid drugs, tissue distribution and elimination, kinetics
(rats), 26, 31
RG 14620, dispositional characteristics, intravenous
administration or
dermal application (rats, rabbits), 216Risperidone, metabolism
and excretion, oral administration (rats, dogs),
129RNA, messenger, suppression of cytochrome P450 2Cl 1 levels,
modula-
tion of liver microsomal cyclophosphamide and ifosphamide
acti-vation (rats), 673
RU44403, pharmacokinetics (rats), 601
RU44507, active form, pharmacokinetics (rats), 601
Salicylate, renal transport of inorganic sulfate inhibition,
membrane yes-ide preparations (mice), 318
SCH 23390, glucuronidation by liver microsomes (humans), 713SCH
39166, glucuronidation by liver microsomes (humans), 713SDZ 1MM
125, absorption and disposition, single and repeated adminis-
tration (rats), 194
Seraspenide, pharmacokinetics, healthy volunteers and patients,
843
Serum, A-esterase, detoxification of paraoxon, kinetic mechanism
(hu-mans), 472
Simvastatin, metabolic disposition, patients with T-tube
drainage, 139SK&F 1 10679 (growth hormone-releasing peptide),
disposition, intrave-
nous or subcutaneous administration (rats, dogs), 90Skin,
absorption of DEET, pharmacokinetic assessment (cattle),
106SM-10888, and metabolites, pharmacokinetics depending upon
physico-
chemical properties, 294
Spironolactone, hepatic metabolism, production of
3-hydroxy-thiomethyl
metabolites, 903
Steroids, substrates, liver UDP-glucuronosyltransferase with
activity to-
ward, stable expression (humans), 799Stiripentol, metabolic
chiral inversion
influence of administration route (rats), 554
mechanistic studies (rats), 544
Sulfate
homeostasis, acetaminophen-induced alterations, deficient
dietary in-take of sulfur (rats), 725
inorganic, renal transport, inhibition by salicylate, membrane
vesicle
preparations (mice), 318
Tacrine, stereoselective hydroxylation (rats, humans),
719Taxol
distribution, biliary secretion, and metabolism, effect of
cimetidine,
probenecid, and ketoconazole (rats), 254
6a-hydroxytaxol, isolation and identification, liver microsomes
(hu-mans), 177
Terfenadine, metabolism, liver, in vitro inhibition by macrolide
antibioticsand azole antifungals (humans), 849
Testosterone, formation of 16a-hydroxyandrostenedione, purified
P450
2Cl I (rats), 584Tetrachlorodibenzo-p-dioxin, -induced
CYPI-related P450s, TCDD��J�,
and TCDDAHH, hepatocytes as major locus, embryo liver
(chicks),962
Tetraplatin, pharmacokinetics, administered intraperitoneally
with re-
duced glutathione (mice), 312
Thapsigargin, metabolism in hepatocytes (rats), 433
Theophylline, N-demethylations, probes for P45O1AI and P4501A2,
827Thiabendazole, formation of toxic metabolites, identification of
thioam-
ides as ring cleavage products (mice), 750
Thiazoles, formation of toxic metabolites, identification of
thioamides asring cleavage products (mice), 750
Thioamides, identification as ring cleavage products, formation
of toxic
metabolites from thiazoles (mice), 750Tissue distribution
studies, routine, for approval of human drugs, purpose
and cost effectiveness questioned (letter), 341
Transferrin receptor, monoclonal antibody to, and conjugate of
avidin,biotin bound to, pharmacokinetics and saturable blood-brain
bar-
rier, 99Trichloroethylene, metabolism, quantification, vial
equilibration method,
comprehensive evaluation, 858Tropisetron, metabolism, CYP2D6
involvement, 269Tyrosine kinase inhibitor (RG 14620), dispositional
characteristics, intra-
venous administration or dermal application (rats, rabbits),
216
UDP-glucuronosyltransferase, liver, stable expression, with
activity to-
ward steroid and xenobiotic substrates (humans), 799
Urine
disposition of2O(S)-camptothecin, lactone and carboxylate forms
(rats),
438
excretion of chromium, following ingestion of chromium
picolinate
(humans), 522major metabolite of m-chlorophenylpiperazine,
isolation and identifica-
tion (rats), 171
metabolites of isbufylline, isolation, identification, and
synthesis (hu-
mans), 259
metabolites of (R),(R)-labetalol, 866metabolites of nefazodone,
characterization (humans), 304
Usnic acid, induction of murine cytochrome P450 3A, 663
Valaciclovir
metabolic disposition (rats), 60metabolic fate and
pharmacokinetics (monkeys), 55
Valproate, site-dependent intestinal hydrolysis (rats),
120Valproic acid, disposition and protein binding (rats),
113Verapamil, kinetic interaction with diltiazem, isolated perfused
liver
(rats), 530Volatile organic chemicals, metabolism,
quantification, vial equilibration
method, comprehensive evaluation, 858Vulpinic acid, induction of
murine cytochrome P450 3A, 663
-
SUBJECTINDEX 989
Warfarin, metabolism by hepatic microsomes, inbred strains
(rats), 607 substrates, liver UDP-glucuronosyltransferase with
activity toward, sta-WR24251 1, pharmacokinetics and
kinetic-dynamic modeling, 358 ble expression (humans), 799WR-2721
(ethyol, amifostine), metabolic pathways (BALB/c mouse), 895
Xenobiotics Z&inoni, Vincent G., dedication, 1
diethyldithiocarbamate methyl ester, regioselective S-oxidation,
liver �t0setr0fl, in vitro metabolism, interspecies comparison and
role of CYPmicrosomes (rats), 324 3A, 352
-
4
.�
.�.
L.
you can get copies of any article published inany Williams &
Wilkins journal. It’s fast -
RATES, PER ARTICLE
1-5 pages
6-10 pages
11-15 pages
16-20 pages
21-25 pages
26+ pages
$10
$12
$15
$18
$20
$25
Call toll-free from the U.S.orCanadato 1-800-354-9685, or fax
this form to1-410-528-4312, ormail
to the address on the
order form.
©Williams & WilkktsA WAVERLY COMPANY($20, Federal
Express)
Exp. Date I
_______________________________________________________Ilnstitution
_________________________________________ I
� I:�L�� phone, or mailyour citation to:
Address______________________________ I
I Williams & Wilkins I Quick Copies City/State/Zip II 428 E.
Preston street / Baltimore, MD 21202-3993
L� - - �_#
Fax#___________________________________________________________________________________________________________I
DDSAD 55429
9
\Vifliams &Wffl�ns Quick Copies.Tellus today Read it
tomorrow
because we’re the primarysource, we can fax anarticle to you
within 24 hours ofwhen we receive
your request. It costs less - there are no copyright
fees and the cost offaxing is included in the
price. It’s affordable - look at the table to the right.
Williams & Wilkins Quick Copies. Tell us today.
______________
Read it tomorrow.- ORDERFORM
I PLEASE SEND ME THIS ARTICLE: PAYMENT:I Journal Title
____________________________________ � Check enclosed (to Williams
& Wilkins)I Volume/Issue/Year_______________________________ E
Charge VISA El Charge MasterCard
Beginning/Ending Page #________ Number ofcopies..............
Acct. #_ ________Author Signature_
Article Title _____________________________________ SHIP TO:
DELIVERY: Name
� Fax � First class mail
n Air mail E Federal Express
-
DRUG METABOLISM AND DISPOSITION
Raymond F. Novak, Editor
Russell Prough, Gerald Miwa, and Stephen P. Spielberg, Associate
EditorsElizabeth Sherman, Assistant to the Editor
Editorial Advisory Board
Ghulam A. S. AnsariArthur AtkinsonThomas BaillieJohn R.
BendTerrence F. Blaschke
Kenneth Brouwer
Alan R. BuckpittArthur K. Cho
Catherine Fenselau
Joseph Gal
Frank J. GonzalezFrederick Peter GuengenchPhillip S.
Guzelian
James R. HalpertRobert Hanzlik
Ronald N. Hines
Paul F. HollenbergMargaret 0. James
Fred F. KadlubarLaurence S. Kaminsky
Ralph E. KauffmanGregory L. Kedderis
Dennis R. KoopSerrine S. Lau
John J. Lech
Anthony Y. H. Lu
Bettie Sue Masters
Charlene A. McQueenBruce Mico
Terrence J. Monks
Edward T. Morgan
Sidney D. NelsonRichard T. OkitaMichael J. Olson
Curtis Omiecinski
Andrew Parkinson
Cecil B. Pickett
Lance R. PohI
John J. Reiners, Jr.
Kenneth W. Renton
Arleen B. Rifkind
Robert Ronfeld
Dhiren Thakker
William Trager
Steve U nger
Mary Vore
Paul A. Watkins
David J. Waxman
Richard M. Weinshilboum
Ronald E. White
Steven A. Wrighton
Garold S. Yost
Board of Publications Trustees
Kenneth E. Moore, ChairmanD. Craig Brater
William A. Catterall
Marlene L. CohenT. Kendall HardenJohn A. Harvey
Raymond F. NovakMarcus M. Reidenberg
Robert E. Stitzel
Executive Officer
Kay A. Croker
VOLUME 22
1994
-
Copyright © 1994 by The American Society for Pharmacologyand
Experimental Therapeutics
-
THE JOURNAL OFPHARMACOLOGYAND
EXPERIMENTAL THERAPEUTICSEditor: John Harvey, PhD, The Medical
Collegeof Pennsylvania
JPET is respected the world over as one ofthe leading
researchjournals in the field ofpharmacology. Readers find
broadcoverage ofall aspects ofthe interactions ofchemicals
withbiological systems, including:
. autonomic pharmacology #{149}drug abuse
. analgesia drug metabolism
. behavioral pharmacology & disposition
. cardiovascular . gastrointestinalpharmacology pharmacology
. cellular pharmacology . immunopharmacology
. chemotherapy . neuropharmacology
. clinical pharmacology . pulmonary pharmacology
. developmental . renal pharmacologypharmacology .
toxicology
JPET is valuable reading for academic, industrial arid
clinical
pharmacologists as well as toxicologists. Thejournal deserves
aplace in every pharmaceutical and toxicological researchlaboratory
and pharmacology/toxicology department through-out the world.
Monthly
r - - - - - - - - - - - - - - - - - - -
Avoid future rate increases and ensure uninterrupted
service--enter Payment options:your multiyear subscription today! D
Check encli )SCd � Bill me
El VISA 0 MasterCard � American Express
TheJournal ofPbarmacology and Experimental Therapeutics
______________________________________(monthly) card �I o
Individual: $190/yr 0 Institutions: $340/yr
__________________________________________________________(Ptease
add$65 outside the US.; in Canad� aLso add 7% GST ) signature RI 0
New Subscription 0 Renewal 0 3 yrs 0 2 yrs 0 1 yr
MD subscribers must add state sales tax. Subscriptions outside
the US and Canada
I must be prepaid, in US dollars only. In Japan, contact
Igaku-Shoin MYW, Ltd.I
______________________________________________________________________
(03) 5689-5400. Rates valid for orders received before October 31,
1995.Pleaseallow 8weeks for delivery ofyour first issue. Surface
mail delivery toI name countr,es outside the US may take up to 16
weeks. Airmail rates available
upon______________________________________________________________________
request.I addres.’, Discounts available to members on all ASPET
publications. SAVE 10% whenI
_______________________________________________________________
ordering two. SAVE 15% when ordering three. SAVE 20% when ordering
all four.I �I Williams & Wilkins i.o. i�#{128}�23291 Broadway
HouseI Baltimore, Maryland 212039990 26 Fulham BroadwayI A WAVERLY
Co�’ip�&r.w London SW6 1AA England
PT 55768 Printed in USA J5068S ZPTT
